Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?
about
Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuseInterleukin-23: as a drug target for autoimmune inflammatory diseasesUnraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic ProteinsAbeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice.Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodiesTargeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.Antibody-based immunotherapy for malignant glioma.Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody.Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers.Novel antibodies targeting immune regulatory checkpoints for cancer therapy.From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.Countering immunotoxin immunogenicity.Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.Development and characterization of an anti-rituximab monoclonal antibody panel.Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies.A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma.
P2860
Q24632128-6AB81B0C-F4DC-4624-B7CD-C775E4A1E8C7Q27009502-C6238156-977D-49C5-AE7D-D09D9F644580Q28066498-327ACA97-B683-4C1A-8608-3933604C278EQ33605644-279C51E4-583E-4C9A-A82F-1E54979A6242Q33804009-3EB91C79-E493-4BB6-8723-3120118A8ED4Q33843281-85FB0BC5-F97D-4AA2-BFB4-19DA7BD89960Q33887448-E40A332C-6D43-48C1-8BAB-ED71B7B5DCAAQ34120472-91ECDC0D-F859-4276-AD6D-DC949A3A03A7Q35602239-23D99F28-6403-408B-A42A-132552C6A336Q35689463-8ECC3762-5CD9-458A-B7D4-E2E255BB75EAQ36453638-06561A57-825F-48D4-9144-A00A0F54A7B4Q36725918-626A698B-AFF4-409F-9F2B-87426DF446D6Q36797398-5CFEE2C7-16AB-4017-8DAA-306D0AFD4A50Q37355464-B8D95BA6-1BBE-4C59-8DBE-F9EE0BAEFB45Q37450799-43C5ADF5-52E4-4E3E-BE2F-4BE5A4844726Q38108836-440A55D5-D983-41EF-81DD-9B2FBE75C0D6Q38644644-14D25E24-FEB1-489B-8DC0-4EDE30C21197Q42573903-35474A33-8083-4DFF-99C9-AE0B04B9BAE0Q47099672-9C88644D-948A-4F3F-82F7-8C995511703BQ50140061-61010226-2A69-4108-B634-0484C55401C8Q50985144-85EE3282-FF30-4204-87BA-DB2341E8E7F4Q52716114-1CC72E25-B6ED-4C9D-9F32-4CCE1A35B740
P2860
Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Will immunogenicity limit the ...... apeutic monoclonal antibodies?
@en
type
label
Will immunogenicity limit the ...... apeutic monoclonal antibodies?
@en
prefLabel
Will immunogenicity limit the ...... apeutic monoclonal antibodies?
@en
P2093
P2860
P1476
Will immunogenicity limit the ...... apeutic monoclonal antibodies?
@en
P2093
Karavodin LM
Krusemeier M
Kuus-Reichel K
P2860
P304
P577
1994-07-01T00:00:00Z